Quarterly ResultJun 11, 2026, 07:36 AM
Aurora Cannabis Reports Record Annual Revenue and EBITDA
AI Summary
Aurora Cannabis announced its full-year and fourth-quarter fiscal 2026 results, highlighting record annual global medical cannabis net revenue of $288.6 million (up 18% YoY) and record annual Adjusted EBITDA of $53.8 million (up 32% YoY). The company also completed the accretive acquisition of Safari Flower Company, adding critical EU-GMP certified capacity. While Q4 revenue saw a 10% increase to $84.8 million, driven by medical cannabis growth, Adjusted EBITDA for the quarter decreased to $9.2 million from $14.1 million in the prior year. Aurora maintains a strong balance sheet with significant cash reserves and no debt.
Key Highlights
- Aurora Cannabis achieved record annual global medical cannabis net revenue of $288.6 million, an 18% year-over-year increase.
- Record annual Adjusted EBITDA reached $53.8 million, up 32% year-over-year.
- Completed the acquisition of Safari Flower Company for $26.5 million to expand EU-GMP certified capacity.
- Q4 2026 total net revenue was $84.8 million, a 10% increase from the prior year.
- Q4 2026 medical cannabis net revenue increased 14% year-over-year to $77.1 million.
- Adjusted EBITDA for Q4 2026 was $9.2 million, down from $14.1 million in the prior year period.
- Maintained a strong balance sheet with approximately $164.7 million in cash and short-term investments and no debt.
Price Impact
More from ACB